

CALCR Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP5688b

Specification

CALCR Antibody (C-term) Blocking peptide - Product Information

Primary Accession Other Accession

P30988 NP 001733.1

CALCR Antibody (C-term) Blocking peptide - Additional Information

Gene ID 799

Other Names Calcitonin receptor, CT-R, CALCR

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CALCR Antibody (C-term) Blocking peptide - Protein Information

Name CALCR (<u>HGNC:1440</u>)

Function

This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.

Cellular Location Cell membrane; Multi-pass membrane protein.

CALCR Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

CALCR Antibody (C-term) Blocking peptide - Images

CALCR Antibody (C-term) Blocking peptide - Background



CALCR is a high affinity receptor for the peptidehormone calcitonin and belongs to a subfamily of seventransmembrane-spanning G protein-coupled receptors. The encodedprotein is involved in maintaining calcium homeostasis and inregulating osteoclast-mediated bone resorption. Polymorphisms inthis gene have been associated with variations in bone mineraldensity and onset of osteoporosis.

CALCR Antibody (C-term) Blocking peptide - References

Nussenzveig, D.R., et al. Endocrinology 136(5):2047-2051(1995)Nakamura, M., et al. Biochem. Biophys. Res. Commun. 209(2):744-751(1995)Egerton, M., et al. J. Mol. Endocrinol. 14(2):179-189(1995)Gorn, A.H., et al. J. Clin. Invest. 90(5):1726-1735(1992)